A Phase II Study of LBH589 [panobinostat], a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Lymphoblastic Leukaemia (ALL) and Acute Myelogenous Leukemia (AML).

Trial Profile

A Phase II Study of LBH589 [panobinostat], a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Lymphoblastic Leukaemia (ALL) and Acute Myelogenous Leukemia (AML).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Aug 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 29 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 29 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top